18F-AV-1451 High Resolution Autopsy Study
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02350634|
Recruitment Status : Completed
First Posted : January 30, 2015
Last Update Posted : October 24, 2018
|Condition or disease||Intervention/treatment||Phase|
|Alzheimer's Disease||Drug: 18F-AV-1451||Phase 1|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||3 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||A High Resolution Autopsy Study Evaluating the Relationship of 18F-AV-1451 PET Imaging and Tau Pathology|
|Study Start Date :||June 2015|
|Actual Primary Completion Date :||May 18, 2018|
|Actual Study Completion Date :||May 18, 2018|
Experimental: Autopsy Cohort
End-of-life subjects (life expectancy < 6 months) consenting to brain donation at autopsy. Subjects will receive a single IV bolus injection of 370 MBq(10 mCi) of 18F-AV-1451.
Subjects will receive a single IV bolus injection of 370 megabecquerel (MBq)(10 millicurie [mCi]) of 18F-AV-1451.
Other Name: [F-18]T807
- Relationship of 18F-AV-1451 scan and pathology [ Time Frame: autopsy within 6 months of scan ]Correlation between 18F-AV-1451 standard uptake value ratio (SUVr) and neuropathology at autopsy.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02350634
|United States, Arizona|
|Banner Alzheimer's Institute|
|Phoenix, Arizona, United States, 85006|
|United States, California|
|University of California, San Francisco|
|San Francisco, California, United States, 94121|